CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01196390
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-06-04T12:58:48.763077+00:00
Published At: 2021-05-04T00:00:00+00:00
Record Updated At: 2026-06-02
Results Posted At: 2021-05-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Esophageal Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Stage IB Esophageal Cancer AJCC v7", "Stage IIA Esophageal Cancer AJCC v7", "Stage IIB Esophageal Cancer AJCC v7", "Stage IIIA Esophageal Cancer AJCC v7", "Stage IIIB Esophageal Cancer AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-06-02"
protocolSection.identificationModule.nctId: "NCT01196390"
protocolSection.identificationModule.officialTitle: "A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2021-05-04"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.